Emerging Cellular Therapies for Anti-myeloperoxidase Vasculitis and Other Autoimmune Diseases

Dragana Odobasic, Stephen R. Holdsworth

Research output: Contribution to journalReview ArticleOtherpeer-review


Anti-myeloperoxidase vasculitis (MPO-AAV) is a life-threatening autoimmune disease which causes severe inflammation of small blood vessels, mainly in the kidney. As for many other autoimmune diseases, current treatments, which consist of general immunosuppressants, are partially effective, toxic and broadly immunosuppressive, causing significant and serious adverse effects in many patients. Therefore, there is an urgent need for more targeted and less harmful therapies. Tolerogenic dendritic cells, regulatory T cells and stem cells have emerged as attractive, new and safer options for the treatment for various autoimmune diseases due to their unique and selective immunosuppressive capacity. In this review, we will discuss how these cellular therapies offer potential to become novel and safer treatments for MPO-AAV.

Original languageEnglish
Article number642127
Number of pages11
JournalFrontiers in Immunology
Publication statusPublished - 29 Jul 2021


  • glomerulonephritis
  • myeloperoxidase
  • regulatory T cells
  • stem cells
  • tolerogenic dendritic cells
  • vasculitis

Cite this